Molecular docking studies revealed the specific bioactive mechanisms of each fraction: CMP1 exerted immunomodulatory effects by interacting with TLR4 and DC-SIGN receptors and exhibited therapeutic potential for brain edema or glioma via targeted binding to AQP4. This evidence concerns the gene TLR4 and central nervous system cancer.